84 results about "In vitro proliferation" patented technology

The invention discloses an application of LDLR in screening or preparing a medicine for treating acute myelogenous leukemia, the expression level of the LDLR in acute myelogenous leukemia cells is detected for the first time so as to characterize the conditions of proliferation, apoptosis, cycle and the like of the acute myelogenous leukemia cells, and the LDLR is taken as a target spot; by knocking down the expression quantity of the LDLR, the proliferation of acute myelogenous leukemia cells can be inhibited, the apoptosis of the acute myelogenous leukemia cells can be promoted, the cycle of the acute myelogenous leukemia cells can be retarded in the S phase, the in-vitro proliferation of the acute myelogenous leukemia cells can be accurately and effectively inhibited, and the application prospect is wide. A new thought and a new direction are provided for screening or preparing the medicine for diagnosing and treating the acute myelogenous leukemia.

Disclosed are an ecteinascidin compound and a use thereof. The present invention provides a compound as shown in formula (I), or a pharmaceutically acceptable salt, ester, stereoisomer, tautomer, polymorph, solvate, isotope-labeled compound, metabolite, or prodrug thereof. The compound provided by the present invention exhibits one or more effects selected from the following group: (1) having inhibitory activity on in vitro proliferation of tumor cells; (2) having in vivo antitumor effect; (3) having in vivo tumor-targeting ability; and (4) having good in vivo safety.

Disclosed in the present invention are an ecteinascidin compound and the use thereof. Provided in the present invention is a compound as represented by formula (I), or a pharmaceutically acceptable salt, an ester, a stereoisomer, a tautomer, a polymorph, a solvate, an isotopically labeled compound, a metabolite or a prodrug thereof. The compounds provided by the present invention have one or more effects selected from the following group: (1) having an inhibitory activity against tumor cell proliferation in vitro; (2) having a tumor inhibition effect in vivo; (3) having an in vivo tumor targeting capability; and (4) having good safety in vivo.

A human chronic myeloid leukemia cell line and the use thereof. The human chronic myeloid leukemia cell line is the first cell line internationally established from chronic-phase leukemia cells of chronic myeloid leukemia, and was named human chronic myeloid leukemia cell YYXY-M6, which was deposited at the China Center for Type Culture Collection (Wuhan University, Wuhan, China) on July 24, 2023, under the deposit number of CCTCC NO: C2023219. The leukemia cell line exhibits primitive cell morphology and has three karyotypes, i.e. t(6:11)(q25:q23), del(11)(q23) and normal karyotype (46, XX); is BCR-ABL gene-negative; has good in-vitro proliferation ability; can be used as cellular material for the study of the mechanism of occurrence and development of the chronic phase of chronic myeloid leukemia, from the chronic phase thereof to the blastic phase thereof, and of BCR-ABL gene-negative chronic myeloid leukemia, and for the in-vitro study of individualized treatment; and can also be used for both in-vitro and in-vivo studies of drug screening and evaluation for the chronic phase of chronic myeloid leukemia, from the chronic phase thereof to the blastic phase thereof, and BCR-ABL gene-negative chronic myeloid leukemia, providing guidance for clinical medication.

The invention relates to application of salicin in preparation of a medicine for preventing and / or treating osteoporosis, and belongs to the technical field of medical treatment. The invention provides application of salicin in preparation of a medicine for preventing and / or treating osteoporosis. The salicin can promote in-vitro proliferation and migration of hBMSCs and hASCs, reduce the oxidative stress level of cells, promote osteogenic differentiation of the cells by influencing an AMPK signal channel, and inhibit apoptosis and bone loss by removing ROS in bone tissue and up-regulating expression of endogenous antioxidant enzyme, can be used for treating osteoporosis, and has good biological safety.

The present invention provides use of an MAPK12 inhibitor and a derivative thereof in the preparation of an anti-tumor drug, and particularly relates to the technical field of medicines. The MAPK12 inhibitor (i.e., MIM2) can effectively inhibit the in vitro proliferation ability of colorectal cancer, gastric cancer, pancreatic cancer, and breast cancer cells. MIM2 can effectively inhibit the in vivo proliferation ability of colorectal cancer in NSG mice, and is expected to be used as an anti-tumor small molecule drug in the treatment of colorectal cancer, gastric cancer, pancreatic cancer, breast cancer, and other tumors.

An anti-GPC3 antibody drug conjugate that specifically binds to GPC3 and a use thereof. The anti-GPC3 antibody drug conjugate has a structure as shown in formula (I-1). The anti-GPC3 antibody drug conjugate has better inhibitory activity on in-vitro proliferation of tumor cells and a better in-vivo tumor suppression effect.

The invention belongs to the technical field of biomedicine, and relates to a human bladder cancer cell line ZSZB1 with primary cis-platinum drug resistance and application thereof. The cell line is preserved in the China Center for Type Culture Collection (CCTCC), the preservation number is CCTCC No: C2024120, and the cell line is derived from a radical operation specimen of primary chemotherapy drug-resistant bladder cancer patients of Chinese population, and has stable in-vitro multiplication capacity and primary cis-platinum drug-resistant characteristic. The ZSZB1 provides an ideal experimental model for bladder cancer pathogenesis research, cis-platinum drug resistance mechanism exploration and novel antitumor drug screening. Establishment of the cell line can effectively promote transformation from basic research of bladder cancer to clinical application, and the cell line is of great significance to promotion of precise medical development.

The invention discloses a pharmaceutical composition for inducing leukemia cell copper death and application thereof, and relates to the technical field of tumor cell apoptosis. The active ingredients of the pharmaceutical composition are oleanolic acid and illlisemom. It is found for the first time that oleanolic acid can significantly up-regulate expression of a copper death key regulatory factor FDX1, when oleanolic acid is used in combination with a copper ion carrier Ilismor, a large synergistic effect can be generated through an FDX1 / DLAT axis, leukemia cells are significantly induced to generate copper death, and therefore in-vitro proliferation and in-vivo tumor forming ability of the leukemia cells are effectively inhibited. The composition provides a new drug development strategy with a clear mechanism for treatment of leukemia, especially drug-resistant leukemia.

The present disclosure relates to cultured tissue, methods for production of the cultured tissue, e.g., cultured meat, that is not genetically modified. Further, the disclosure provides method of temporary immortalization of cells for propagation in vitro.

The invention discloses a cell culture medium supplement as well as a preparation method and application thereof, and relates to the technical field of cell biology. The supplement comprises DL-alpha-tocopheryl acetate, linolenic acid, ethanolamine, L-carnitine hydrochloride, 3, 3 ', 5-triiodoL-sodium thyrosinate, and serum albumin. As a cell culture additive with definite chemical components and simple composition, the cell culture additive can replace a traditional culture system with unknown chemical components or too complex composition, and is used for supporting proliferation, differentiation and characterization analysis of cells. The culture medium additive is clear in chemical component, simple to prepare, stable in effect and relatively low in cost, can promote in-vitro proliferation and oxidation resistance of cells including human embryonic stem cells and mesenchymal stem cells, and has important application value in actual production.

The present invention belongs to the technical field of pharmaceutical chemistry, and discloses a paeonol Mannich base-rhein conjugate, a preparation method thereof and an application thereof. The conjugate is a compound represented by the general formula (I) or (II) or a pharmaceutically acceptable salt thereof. Compared with the clinically commonly used anti-tumor drugs fluorouracil and paeonol, the conjugate of the present invention has significantly higher in vitro proliferation inhibitory activities against human liver cancer cells (HepG2) and human lung cancer cells (A549), and the in vitro proliferation inhibitory activities of most compounds against human cervical cancer cells (Hela), human colon cancer cells (HT29) and human osteosarcoma cells (U2OS) are significantly better than those of fluorouracil and paeonol, indicating excellent anti-tumor effects. Moreover, the conjugate of the present invention has good water solubility and is expected to be applied to the treatment of various cancers such as cervical cancer, colon cancer, osteosarcoma, lung cancer or liver cancer, and has broad clinical application prospects.

The invention relates to a preparation for promoting in-vitro proliferation of pancreatic stem cells and application of the preparation. A nucleotide sequence of a miR-802 inhibitor comprises a sequence as shown in SEQ ID No. 1. According to the composition containing the miR-802 inhibitor, the in-vitro proliferation capacity of pancreatic stem cells is remarkably improved, and the capacity of pancreatic duct cells for forming pancreatic stem cell colonies is remarkably improved. Experiments prove that the miR-802 inhibitor has the functions of promoting dry gene expression and inhibiting endocrine differentiation gene expression in pancreatic stem cells cultured in vitro.

The invention discloses an application of SB216763 in improving the in-vitro proliferation capacity of porcine spermatogonium. Therefore, the SB216763 can be used as an additive of the porcine spermatogonial cell in-vitro culture medium, and the porcine spermatogonial cell in-vitro culture medium combined with various growth factors is prepared. Researches show that clone groups of the porcine spermatogonium cultured by the culture medium additionally added with the SB216763 are increased, the number of the clone groups is remarkably increased, the expression quantity of genes related to proliferation is remarkably increased, apoptosis genes are remarkably reduced, and the expression of genes related to reproductive specificity and pluripotent maintenance is also increased, so that the in-vitro proliferation and long-term maintenance of the porcine spermatogonium are improved, and the porcine spermatogonium can be used for preparing a novel culture medium for the porcine spermatogonium. Therefore, the in-vitro culture level of the PSCs is systematically improved. Therefore, the invention provides a reliable basis for establishing a long-term, stable and efficient in-vitro culture system of the porcine spermatogonium, and provides a stable and efficient cell model for gene editing of the porcine spermatogonium, preparation of transgenic animals and research on reproductive diseases; the method also has potential application value in the aspects of genetic improvement of pig breeds or preservation of male germplasm resources.

This invention discloses a jugnitin compound and its applications. The invention provides a jugnitin compound, which is a compound of formula (I), or a pharmaceutically acceptable salt, stereoisomer, or tautomer thereof; the compound provided by this invention has one or more effects selected from the group consisting of: (1) inhibitory activity against the in vitro proliferation of tumor cells; (2) in vivo tumor-suppressive effect; (3) in vivo tumor-targeting ability; and (4) good in vivo safety.

The present application relates to bovine tuberous skin disease virus, in particular, to bovine tuberous skin disease virus ORF145 gene deletion strain and its application. The gene deletion strain is characterized in that it is constructed by deleting ORF145 gene from bovine tuberous skin disease virus virulent strain LSDV XJ201901. Compared with the parent strain, the replication level of the constructed deletion strain rLSDVΔ145 in in vitro cells is equivalent to that of the parent strain, indicating that the gene deletion does not affect the in vitro proliferation ability of the virus. In addition, after rLSDVΔ145 infects MDBK cells, it can significantly reduce the mRNA expression level of pro-inflammatory factors IL-1beta and IL-6, while not interfering with the expression of IFNbeta mRNA. Further transcriptomic analysis shows that the deletion strain significantly reduces virulence and pathogenicity on the basis of maintaining good immunogenicity; it not only loses the inhibition ability to the innate immune pathway, but also can effectively activate the adaptive immune response, and significantly reduce the risk of inflammation and tissue damage, showing significant potential as a safe and efficient attenuated live vaccine.

The present invention relates to an immune cell co-expressing IL-15 and a chimeric antigen receptor containing an OX40 ligand as an intracellular signal domain, and a composition for preventing or treating cancer comprising the same as an active ingredient. The immune cell shows synergistic tumor cell killing activity through co-expression of the chimeric antigen receptor and IL-15, and the survival rate and the in-vitro proliferation rate of the immune cell are remarkably improved, so that the immune cell can be used as an efficient anti-cancer cell therapy. Particularly, when the chimeric antigen receptor targeting CD5 is expressed, the immune cell can be used as an effective treatment composition for various CD5 positive tumors, including lymphocytic leukemia.

The invention provides the application of the Chaetomugilin Q in preparation of the medicine for treating the tumors, the research proves that the Chaetomugilin Q can regulate and control the pathway of pathways in caner and the pathway of EGFR (epidermal growth factor receptor) tyrosine kinase inhibitor caner, and particularly, the Chaetomugilin Q can remarkably inhibit in-vitro proliferation of cancer cells of breast cancer, prostatic cancer, liver cancer, melanoma or leukemia, so that the Chaetomugilin Q has the application prospect in tumor treatment.

Compositions and methods are provided for modifying eukaryotic cells, e.g., to express a transgene of interest and / or to generate a population of expanded cells ex vivo.SOLUTION: A method of transducing a population of eukaryotic cells, such as a population of pluripotent cells, to express a gene of interest by contacting the cells with a viral vector, e.g., a lentiviral vector, and a diblock copolymer, e.g., a diblock copolymer comprised of a hydrophilic region and a hydrophobic region. For example, the diblock copolymer can be composed of polyoxyethylene (PEO) subunits and polyoxypropylene (PRO) subunits. In addition, the compositions and methods of the invention can be used to promote the ex vivo expansion or survival of a population of pluripotent cells (e.g., CD34 + hematopoietic stem or progenitor cells), for example, by contacting the cells with a diblock copolymer.SELECTED DRAWING: None

The invention provides human phagocytic cells which are not tumorigenic, yet still capable of cell division ex-vivo, such as in cell culture. A culture containing these cells can be expanded manyfold, that is the cell number in such a culture can be increased by a factor of 10 or more. The cells show characteristics of functional phagocytes in a differentiated state and are capable to alleviate pathological defects in in vivo models.

A hematopoietic stem cell (HSC) proliferation medium includes a basal medium, 0.1 ng / mL to 200.0 ng / mL of thrombopoietin (TPO), 0.1 ng / mL to 200.0 ng / mL of stem cell factor (SCF), 0.1 ng / mL to 20.0 ng / mL of interleukin-3 (IL-3), 0.1 ng / mL to 100.0 ng / mL of interleukin-6 (IL-6), 0.1 ng / mL to 200.0 ng / mL of Flt-3 ligand (FL), 0.1 μg / mL to 20.0 μg / mL of insulin, 0.1 μg / mL to 120.0 μg / mL of transferrin, 0.1 g / L to 3.0 g / L of human serum albumin (HSA), 0.1 μM to 4.0 μM of pyrimido-indole derivative UM729, and 0.1 μM to 2.0 μM of aryl hydrocarbon receptor (AhR) antagonist StemRegenin 1 (SR1). Methods for in vitro proliferation of hematopoietic stem cells (HSCs) and in vitro production of hematopoietic progenitor cells (HPCs) using the HSC proliferation medium are also provided.

The invention discloses an HMGB3 inhibitor and application of the HMGB3 inhibitor in preparation of a medicine for treating liver cancer, and relates to the field of molecular biology and biological medicine. The application has the advantages that HCC cell proliferation and clone formation are inhibited through HMGB3shRNA, so that HCC transplanted tumor growth is inhibited, HMGB3 is knocked down to up-regulate expression of TNF, NFKBIA and other genes and down-regulate expression of CARD11 and other genes, NF-kappa B nuclear translocation degradation IKK is further inhibited, in-vitro proliferation and invasion ability of hepatocellular carcinoma cells can be seriously affected, development of liver cancer can be inhibited, and the application has a good application prospect. The compound can be used for preparing anti-hepatoma drugs.

The present invention provides an anti-B7H4 antibody-drug conjugate that specifically binds to B7H4 and a composition comprising the same, the structure of the anti-B7H4 antibody-drug conjugate being as shown in formula (I-1). The present invention further provides a method and use of the antibody-drug conjugate of the present invention. The anti-B7H4 antibody-drug conjugate of the present invention has better inhibitory activity against the in vitro proliferation of tumor cells and better tumor inhibitory effect in vivo. [Formula 1] JPEG2025510606000106.jpg66165

The invention belongs to the field of immune drug development. The invention particularly relates to a T cell in-vitro proliferation culture method and application thereof. By changing the coating amount of the anti-CD3e antibody and the concentration combination of beta-mercaptoethanol with different concentrations in the T cell culture medium provided by the invention, the effect of accurately controlling the background proliferation of the T cells is achieved; the kit prepared from the related raw materials of the method is used for detecting the activity of the immune preparation.

The invention provides application of an overexpressed ifitm3 gene in promoting in-vitro steady state maintenance of oogonial stem cells of paralichthys olivaceus, and belongs to the technical field of gene engineering. The overexpression vector containing the ifitm3 gene is constructed and transfected to the oogonial stem cells of the paralichthys olivaceus, so that the in-vitro proliferation activity and migration ability of the stem cells can be remarkably enhanced, and the undifferentiated state and the stemness characteristic of the stem cells are effectively maintained. The technology provides a key means for in-vitro long-term culture, directional induced differentiation and excellent germplasm resource preservation of paralichthys olivaceus oogonial stem cells, and has important application value in fish reproductive biology research, gene editing breeding and culture industries.

The application discloses a fetal bovine serum-free milk tooth dental pulp stem cell culture system and application thereof. The application realizes that fetal bovine serum is replaced by low-dose human serum, the milk tooth dental pulp stem cell is cultured by being added into a basic culture medium, and the proliferation of the milk tooth dental pulp stem cell is not inhibited in the culture process. Further, CGF is added and combined with HS to replace FBS in a conventional stem cell culture medium, and low-concentration HS and CGF can promote the in-vitro proliferation and differentiation of SHED, and a sufficient amount of CGF can be extracted to expand SHED without extracting a large amount of blood. Therefore, the application provides a FBS substitute which is derived from human body, has high safety and has few ethical disputes, foreign factors in the SHED culture system are completely eliminated, the influence of external factors contained in FBS on the in-vitro expansion of SHED is eliminated, and SHED can be expanded to a clinical scale without affecting the stemness of SHED.

A use of Niemann-Pick C1 (NPC1) protein and a substance that inhibits NPC1 gene expression and / or protein activity, which is selected from at least one of the following (a)-(h): (a) for the preparation of kits for diagnosing cancer; (b) for the preparation of kits for predicting the prognosis of cancer; (c) for the preparation of kits for performing a companion diagnostic for cancer treatment; (d) for the preparation of drugs for the prevention and / or treatment of cancer; (e) for the preparation of drugs for the prevention and / or treatment of cancer spread and metastasis; (f) for the preparation of drugs for promoting apoptosis of cancer cells; (g) for the preparation of drugs for inhibiting cancer cells from developing into cancer; (h) for the preparation of drugs for inhibiting in vitro proliferation and growth of cancer cells.

The invention discloses a method for improving killing activity of NK cells, and belongs to the technical field of cellular immunity. Carrying out segmented in-vitro culture on the separated NK cells by adopting a specific basic induction culture medium, an activation induction culture medium and an amplification culture medium, wherein recombinant human insulin and sodium selenite are added into the basic induction culture medium; ganoderma lucidum polysaccharides, eicosapentaenoic acid, IL-15 and IL-18 are added into the activation and induction culture medium. Salidroside, tea polyphenol, low molecular weight chitosan, IL-2 (interleukin-2), IL-21 (interleukin-21) and SCF (mesenchymal stem cells) are added into the amplification culture medium. According to the method, the killing ability of the NK cells obtained through in-vitro culture on tumor cells and the in-vitro proliferation effect of the NK cells are remarkably improved, the problems that in the prior art, the in-vitro proliferation efficiency of the NK cells is low, and cell activity is difficult to consider are solved, and a foundation is laid for clinical transformation of NK cell immunotherapy.

The invention provides a method for constructing a hepatic progenitor cell-like cell bank, including successively performing following processes to human primary hepatocyte cultures from different donor sources: transformation-culture, cryopreservation treatment, proliferation-culture, a first subculture treatment, virus infection, a second subculture treatment, continuous selection-culture and continuous subculture. In the method for constructing a heterogenous immortal hepatic progenitor cell-like cell bank of the present invention, the human primary hepatocyte culture of each of the donor sources is transformation-cultured before the proliferation-culture, which is beneficial in endowing the human primary hepatocyte cultures with good proliferation performance. Once combined with subsequent controlling of culture parameter, the immortal hepatic progenitor cell-like cell lines obtained from different donor sources may have good in vitro proliferation ability. The invention also provides an application of the hepatic progenitor cell-like cell bank and cell lines obtained by the construction method.

The invention discloses an ecteinin compound and an application thereof. The invention provides a compound as shown in a formula (I), or pharmaceutically acceptable salt, ester, stereoisomer, tautomer, polymorphic substance, solvate, isotope label, metabolite or prodrug thereof. The compounds provided by the invention have one or more effects selected from the following groups: (1) the compounds have inhibitory activity on in-vitro proliferation of tumor cells; (2) an in-vivo tumor inhibition effect is achieved; (3) the polymer has in-vivo tumor targeting ability; and (4) the compound has good in-vivo safety.